Neurocrine Biosciences
NBIX
#1613
Rank
NZ$22.60 B
Marketcap
NZ$225.20
Share price
-1.19%
Change (1 day)
33.27%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): NZ$8.23

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is NZ$8.29. an increase over its 2024 EPS that were of NZ$5.81.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025NZ$8.0237.87%
2024NZ$5.8133.07%
2023NZ$4.3757.76%
2022NZ$2.7769.47%
2021NZ$1.63-78.21%
2020NZ$7.50990%
2019NZ$0.6981.82%
2018NZ$0.38-113.5%
2017NZ-$2.800.62%
2016NZ-$2.7957.28%
2015NZ-$1.7725.61%
2014NZ-$1.4118.84%
2013NZ-$1.19-1085.71%
2012NZ$0.12

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$2.34-71.78%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$4.11-50.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$39.61 377.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
NZ$1.50-81.95%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
NZ-$3.49-142.12%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
NZ$2.94-64.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
NZ-$51.44-720.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
NZ$3.02-63.56%๐Ÿ‡ฌ๐Ÿ‡ง UK